$VRTX

Vertex Pharmaceuticals (VRTX) stock has risen 16.56% in 30 days and 24.87% in 90 days, with a 1-year total return of 40.57%, following the FDA's expansion of Casgevy's label to include younger patients. The company's shares are near analyst targets, with a fair value estimate of $558.68, suggesting a 10% undervaluation. However, investors should monitor its reliance on cystic fibrosis drugs and pipeline risks.

Citigroup analyst Geoff Meacham ranks Vertex Pharmaceuticals (VRTX) as a top biotech pick after its $10 billion acquisition of Crinetics. The deal adds endocrinology to Vertex's portfolio, with Citigroup projecting $700M in PALSONIFY sales by 2030. Vertex maintains a Buy rating and $585 price target. The company expects the deal to be accretive to non-GAAP operating income by 2029. Vertex was also added to Bank of America's US 1 List.

Vertex Pharmaceuticals (VRTX) has a consensus 'Moderate Buy' rating from 30 analysts, with a mean price target of $566.65, implying a 3.5% upside from current levels. Analysts are generally bullish on the company's prospects, according to Barchart.com.

Goldman Sachs updated its Conviction Lists, adding Vertex Pharmaceuticals (VRTX) to the U.S. list and Adyen, RWE, and Talanx to the European list. Vertex is seen as well-positioned for long-term growth, while Adyen has a 77% upside target. RWE and Talanx also have significant upside potential according to Goldman's analysts.

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

Crinetics Pharmaceuticals (CRNX) director Weston Nichols received $85 per share in cash as part of the company's merger with Vertex Pharmaceuticals. His stock options were canceled, with those below $85 exercise price converted to cash, while others received no consideration. The merger was effective September 1, 2026.

VERTEX PHARMACEUTICALS INC / MA (VRTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive

Goldman Sachs updated its U.S. and European conviction lists for September. In the U.S., Vertex Pharmaceuticals was added, while Interactive Brokers was removed. In Europe, RWE, Adyen, and Talanx were added, with Enel, Wise, Hannover Re, and Zalando removed. Analysts highlighted growth prospects and raised price targets for some companies.

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics, adding PALSONIFY and atumelnant with a combined peak revenue potential of over $5B. The deal is expected to be accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes to oversee integration and growth strategies.

Vertex Pharmaceuticals has completed its $10B acquisition of Crinetics Pharmaceuticals. Jonathan Poole, currently SVP of finance, will become Vertex's CFO in 2027. Charles Wagner, current COO and CFO, will oversee integration. Jasper van Grunsven joins as EVP and chief pain and new product planning officer.